论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
miR-21 在指导骨肉瘤化疗中的临床意义
Received 24 May 2021
Accepted for publication 16 August 2021
Published 29 September 2021 Volume 2021:14 Pages 1247—1261
DOI https://doi.org/10.2147/PGPM.S321637
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Martin H Bluth
Objective: The present study aims to explore the correlation between osteosarcoma (OS) chemosensitivity and the expression levels of serum and tumor tissue micro-ribonucleic acid-21 (miR-21).
Methods: The relevant miR-21 expression levels in 30 patients with OS were detected, and the gender, age, tumor location, pathological type, Enneking stage, and miR-21 expression changes before and after chemotherapy were retrospectively analyzed.
Results: Serum and tumor tissue miR21 expression levels were significantly higher in patients with OS than in control subjects; the serum miR-21 expressions before and after chemotherapy were not related to patient age and gender. The effective chemotherapy group showed significant differences in miR-21 expression levels before and after chemotherapy.
Conclusion: Serum and tumor tissue miR-21 expression levels in patients with OS are closely related to the effects of chemotherapy, making miR-21 a potential biomarker and therapeutic target for the diagnosis and evaluation of chemotherapy effects on patients with OS.
Keywords: osteosarcoma, tumor tissue, serum, miR-21, chemotherapy